LXRX LEXICON PHARMACEUTICALS
Health Care · Russell 2000
Next earnings: not announced yet
What 8 analyst firms say about LEXICON PHARMACEUTICALS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 8 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 5 reports on LXRX from 5 analyst firms in the last 90 days (8 firms in the past year).
Comparing each firm's latest target with its previous one: 1 lowered it, 2 left it unchanged and 1 has its first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Jefferies lowered its target from $2.18 (set 12 Jun 2026) to $1.69 on 26 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Cantor Fitzgerald | Steve Seedhouse | Buy | 28 Sep 2026 | 8.00 USD |
| Citigroup | Yigal Nochomovitz | Buy | 11 Sep 2026 | 3.10 USD |
| H.C. Wainwright | Joseph Pantginis | Buy | 6 Aug 2026 | 6.00 USD |
| Jefferies | Andrew Tsai | Hold | 26 Oct 2026 | 1.69 USD |
| Leerink Partners | Roanna Ruiz | Hold | 5 Mar 2026 | 2.00 USD |
| Piper Sandler | Yasmeen Rahimi | Buy | 22 Oct 2026 | 6.00 USD |
| Weiss Ratings | Unnamed analyst | — | 21 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 3 Aug 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:57 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.